Intelligent Bio Solutions Completes Recruitment And Begins Subject Screening for FDA 510(k) Pharmacokinetic Study
Portfolio Pulse from Benzinga Newsdesk
Intelligent Bio Solutions (INBS) has completed recruitment and begun subject screening for its FDA 510 pharmacokinetic study. This marks a significant milestone in the company's efforts to bring its product to market.
May 29, 2024 | 12:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Intelligent Bio Solutions (INBS) has completed recruitment and begun subject screening for its FDA 510 pharmacokinetic study. This is a significant step towards regulatory approval and market entry.
Completing recruitment and beginning subject screening for the FDA 510 pharmacokinetic study is a critical milestone for INBS. It indicates progress towards regulatory approval, which is likely to positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100